Receptor-Interacting Protein Kinase 1 (RIPK1) is a serine/threonine protein kinase that plays a critical role in regulating cell death pathways, particularly [necroptosis](/entities/necroptosis)—a programmed form of necrotic cell death. RIPK1 has emerged as a compelling therapeutic target in neurodegeneration due to its involvement in neuroinflammation and neuronal cell death across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Overview
RIPK1 is a member of the RIP kinase family (RIPK1, RIPK2, RIPK3) and contains three functional domains: [@liu2023]
C-terminal death domain (DD): Facilitates interactions with death receptors
Under normal conditions, RIPK1 participates in cell survival signaling through [NF-κB](/entities/nf-kb) activation. However, when dysregulated, RIPK1 can trigger necroptosis—a necrotic form of programmed cell death characterized by membrane rupture and release of pro-inflammatory intracellular contents. [@orme2023]
The Necroptosis Pathway
Necroptosis is mediated by a well-characterized signaling cascade involving RIPK1, RIPK3, and Mixed Lineage Kinase Domain-Like (MLKL): [@re2022]
...
RIPK1 Inhibitors in Neurodegeneration
Receptor-Interacting Protein Kinase 1 (RIPK1) is a serine/threonine protein kinase that plays a critical role in regulating cell death pathways, particularly [necroptosis](/entities/necroptosis)—a programmed form of necrotic cell death. RIPK1 has emerged as a compelling therapeutic target in neurodegeneration due to its involvement in neuroinflammation and neuronal cell death across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Overview
RIPK1 is a member of the RIP kinase family (RIPK1, RIPK2, RIPK3) and contains three functional domains: [@liu2023]
C-terminal death domain (DD): Facilitates interactions with death receptors
Under normal conditions, RIPK1 participates in cell survival signaling through [NF-κB](/entities/nf-kb) activation. However, when dysregulated, RIPK1 can trigger necroptosis—a necrotic form of programmed cell death characterized by membrane rupture and release of pro-inflammatory intracellular contents. [@orme2023]
The Necroptosis Pathway
Necroptosis is mediated by a well-characterized signaling cascade involving RIPK1, RIPK3, and Mixed Lineage Kinase Domain-Like (MLKL): [@re2022]
Mermaid diagram (expand to render)
Key Molecular Events
TNF-α Stimulation: Pro-inflammatory cytokine TNF-α binds to TNFR1, recruiting RIPK1 to the membrane-bound Complex I
RIPK1 Activation: In the presence of caspase-8 inhibition (e.g., by viral proteins or cellular stress), RIPK1 undergoes autophosphorylation
Necrosome Formation: Activated RIPK1 recruits RIPK3 via the RHIM (RIP Homotype Interaction Motif) domain, forming the "necrosome"
MLKL Phosphorylation: RIPK3 phosphorylates MLKL, causing its conformational change and oligomerization
Membrane Permeabilization: Oligomerized MLKL translocates to the plasma membrane, forming pores that cause cell swelling and rupture
RIPK1 in Neurodegenerative Diseases
Alzheimer's Disease
RIPK1 activation is prominently observed in AD brains and contributes to disease pathogenesis through multiple mechanisms: [@yuan2023]
Neuronal Death: RIPK1-mediated necroptosis leads to loss of cortical and hippocampal [neurons](/entities/neurons)
Neuroinflammation: Release of DAMPs (Damage-Associated Molecular Patterns) from necrotic neurons activates [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes)
Amyloid-β Synergy: [Aβ](/proteins/amyloid-beta) oligomers can potentiate RIPK1 activation, creating a vicious cycle
[Tau](/proteins/tau) Pathology: RIPK1 activation may exacerbate tau phosphorylation and aggregation
Studies have shown elevated RIPK1 and RIPK3 expression in AD brain tissue, particularly in regions susceptible to neurodegeneration such as the [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/entorhinal-cortex). [@harris2019]
Parkinson's Disease
In PD, RIPK1 contributes to dopaminergic neuron loss in the substantia nigra pars compacta: [@muffat2022]
[α-Synuclein](/proteins/alpha-synuclein) Toxicity: α-Synuclein aggregates can activate RIPK1 signaling
Mitochondrial Dysfunction: PINK1 and parkin dysfunction (common in familial PD) may sensitize neurons to RIPK1-mediated death
Neuroinflammation: Activated microglia in the substantia nigra show increased RIPK1 expression
RIPK1 inhibitors have demonstrated neuroprotective effects in PD animal models, preserving dopaminergic neurons. [@caccamo2022]
Amyotrophic Lateral Sclerosis (ALS)
RIPK1 activation is a prominent feature in both ALS patient tissue and animal models: [@iannielli2022]
Motor Neuron Degeneration: RIPK1-mediated necroptosis contributes to upper and lower motor neuron death
Glial Cell Activation: Astrocytes and microglia show heightened RIPK1 signaling
Protein Aggregate Stress: [TDP-43](/mechanisms/tdp-43-proteinopathy) and SOD1 aggregates can trigger RIPK1 activation
Post-mortem spinal cord from ALS patients shows widespread RIPK1 and RIPK3 activation in motor neurons and surrounding glia. [@zhao2024]
Frontotemporal Dementia (FTD)
RIPK1 involvement in FTD includes:
Tau Pathology: In FTD-tau cases, tau aggregates associate with RIPK1 activation
TDP-43 Pathology: FTD-TDP cases show RIPK1 activation in affected cortical neurons
Neuroinflammation: Elevated RIPK1 in frontal and temporal cortices correlates with microglial activation
Huntington's Disease
In HD, RIPK1 contributes to striatal neuron vulnerability:
Mutant [Huntingtin](/proteins/huntingtin) Toxicity: mHTT protein promotes RIPK1 activation
Striatal Selective Vulnerability: Medium spiny neurons in the striatum are particularly susceptible to necroptosis
Energy Deficit: Mitochondrial dysfunction in HD sensitizes neurons to RIPK1-mediated death
RIPK1 Inhibitors in Development
Multiple pharmaceutical companies have developed RIPK1 inhibitors, primarily for inflammatory diseases, with potential applications in neurodegeneration: